Fig. 3: Inhibitory effect of Prx II on osteoblast differentiation by increasing PP2A Cα.

a Wild-type and Prx II KO C3H10T1/2 cells were treated with 1 μg of LPS for 1 day. Real-time PCR was performed using the total RNA from these cells as the template. **p < 0.01 compared with the untreated control. ^##p < 0.01 compared with the LPS-treated WT. b C3H10T1/2 cells were transfected with the Prx II overexpression vector and real-time PCR was performed using the total RNA. ***p < 0.005 compared with the untreated control. c Western blot analyses were performed using the indicated antibodies as probes. d C3H10T1/2 cells were transfected with the PP2A Cα overexpression vector and treated with or without BMP2 for 2 days. Real-time PCR was performed using total RNA. **p < 0.01 compared with untreated control. ^#p < 0.05 compared with the BMP-treated group. The protein level of PP2A Cα, the phosphorylation of Smad1/5/9, and the total Smad are shown. e Cells were transfected with the PP2A Cα overexpression vector or the control vector, and PP2A Cα expression was identified by western blot analyses. f PP2A Cα-overexpressing C3H10T1/2 cells were treated with or without BMP2 (0.25 μg/ml) for 30 min. The protein levels of p-Smad1/5/9 and t-Smad were measured by Western blot analyses